August Troendle Sells 15,609 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 15,609 shares of the firm’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $606.47, for a total value of $9,466,390.23. Following the sale, the chief executive officer directly owned 588,369 shares of the company’s stock, valued at $356,828,147.43. This represents a 2.58% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Medpace Price Performance

MEDP stock opened at $620.75 on Friday. Medpace Holdings, Inc. has a one year low of $373.00 and a one year high of $677.90. The stock has a market cap of $17.33 billion, a price-to-earnings ratio of 36.39, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The company has a fifty day moving average price of $550.16 and a two-hundred day moving average price of $492.71.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue was up 17.2% on a year-over-year basis. During the same period in the prior year, the firm earned $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Mizuho raised their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 target price on shares of Medpace in a research note on Thursday, July 23rd. Robert W. Baird upped their price objective on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a report on Friday, July 24th. TD Cowen lifted their target price on Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a report on Friday, July 24th. Finally, Weiss Ratings upgraded shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Three investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $584.18.

Key Headlines Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Institutional Investors Weigh In On Medpace

A number of hedge funds and other institutional investors have recently made changes to their positions in MEDP. NewEdge Advisors LLC boosted its stake in shares of Medpace by 22.1% in the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after buying an additional 190 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. increased its stake in Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after acquiring an additional 37 shares during the period. Sivia Capital Partners LLC bought a new position in Medpace during the 2nd quarter worth $296,000. Finally, M&T Bank Corp raised its holdings in Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after acquiring an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.